Stockreport

Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor PTT-4256 in Patients with Advanced Solid Cancers [Yahoo! Finance]

Bristol-Myers Squibb Company  (BMY) 
Last bristol-myers squibb company earnings: 2/6 07:05 am Check Earnings Report
US:NYSE Investor Relations: bms.com/investors.html
PDF MELBOURNE, Australia and OXFORD, United Kingdom Nov. 20, 2024 /PRNewswire/ -- Pathios Therapeutics ("Pathios"), a biotech company focused on the development of first-in [Read more]